GTH

Genetron Holdings Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.91
-0.39
-2.73%
Closed 16:00 08/03 EDT
OPEN
14.39
PREV CLOSE
14.30
HIGH
14.39
LOW
13.63
VOLUME
43.62K
TURNOVER
--
52 WEEK HIGH
17.71
52 WEEK LOW
11.09
MARKET CAP
1.23B
P/E (TTM)
-3.0832
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GTH stock price target is 19.96 with a high estimate of 20.87 and a low estimate of 19.00.

GTH News

More
Genetron Health to Present at Canaccord Genuity 40th Annual Growth Conference
BEIJING, July 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, today announced that managemen
GlobeNewswire · 5d ago
Genetron Health to Announce Second Quarter Unaudited Financial Results and Host Investor Call on August 6, 2020
BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, today announced that it will report una
GlobeNewswire · 07/27 20:30
The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Repare Therapeutics IPO
Biotech stocks advanced in the week ended July 10 amid mixed news flow emerging out of the sector.
Benzinga · 07/12 15:25
Genetron Health Presents Cancer Clinical Research Data at AACR Virtual Annual Meeting Highlighting the Sensitivity and Specificity of its NGS Technology in Precision Oncology
GlobeNewswire · 06/30 13:55
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26
Shares Of Genetron Holdings Open For Trade At $16.15; IPO Priced At $16/Share
i just counted the number of these things on my window in my officei just counted the number of these things on my window in my office
Benzinga · 06/19 15:39
Genetron Shares Indicated $16.25 On 1.82M Shares
Benzinga · 06/19 14:58

Industry

Healthcare Facilities & Services
+0.78%
Healthcare Providers & Services
+0.20%

Hot Stocks

Symbol
Price
%Change

About GTH

Genetron Holdings Limited is a precision oncology company that specializes in cancer molecular profiling and harnesses technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. The Company operates its businesses primarily within the China market.
More

Webull offers kinds of Genetron Holdings Ltd - ADR stock information, including NASDAQ:GTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GTH stock methods without spending real money on the virtual paper trading platform.